Sequential dose-dense adjuvant therapy with doxorubicin, paclitaxel, and cyclophosphamide

ONCOLOGY

Volumn 11, Issue 4 SUPPL. 3, 1997, Pages 15-18

  Hudis, Clifford ^a,b  

^a Department of Obstetrics Gynecology   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; GRANULOCYTE COLONY STIMULATING FACTOR; METHOTREXATE; PACLITAXEL; TAMOXIFEN;

BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; DRUG MEGADOSE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; NEUTROPENIA; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; FORECASTING; HUMANS; PACLITAXEL;

EID: 0030846198     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (25)

1. Anonymous: Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 33 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 339:1-15,71-85, 1992.
2. Holmes F, Walters R, Thenault R, et al: Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 83:1797-1805, 1991.
3. Reichman BS, Seidman AD, Crown JP, et al: Paclitaxel and recombinant human granulecyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer. J Clin Oncol 11:1943-1951, 1993.
4. Seidman A, Reichman B, Crown J, et al: Paclitaxel as second and subsequent therapy for metastatic breast cancer: Activity independent of prior anthracycline response. J Clin Oncol 13:1152-1159, 1995
5. Gtanni L, Munzone E, Capri G, et al: Paclitaxel in metastatic breast cancer. A trial of two doses by a 3-hour infusion in patients with disease recurrence after prior therapy with anthracyclines. J Natl Cancer Inst 87:1169-1175, 1995.
6. Goldie JH, Coldman AJ, Gudauskas GA Rationale for the use of alternating non-cross- resistant chemotherapy. Cancer Treat Rep 66:439-449, 1982.
7. Day RS: Treatment sequencing, asymmetry, and uncertainty: Protocol strategies for combination chemotherapy. Cancer Res 46:3876-3885, 1986.
8. Norton L, Simon R: Tumor size, sensitivity to therapy, and design of treatment schedules. Cancer Treat Rep 61:1307-1315, 1977.
9. Norton L, Simon R: The Norton-Simon hypothesis revisited. Cancer Treat Rep 70:163-169, 1986.
10. Bonadonna G, Zambette M, Valagussa P: Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes. JAMA 273: 542-547, 1995.
11. Jones RB, Holland JF, Bhardwaj S, et al: A phase I-II study of intensive-dose Adriamycin for advanced breast cancer. J Clin Oncol 5:172-177, 1987.
12. Bronchud MH, Howell A, Crowther D, et al: The use of granulocyte colony-stimulating factor to increase the intensity of treatment with doxorubicin in patients with advanced breast and ovanan cancer. Br J Cancer 60:121-125, 1989.
13. Wood W, Budman D, Korzun A, et al: Dose and dose intensity trial of adjuvant chemotherapy for stage II, node-positive breast carcinoma. N Engl J Med 330:1253-1259, 1994.
14. Lichtman S, Ratain M, Van Echo D, et al: Phase I trial of granulocyte-macrophage colony-stimulating factor (GM-CSF) plus high dose biweekly cyclophosphamide: A CALGB study. J Natl Cancer Inst 85:1319-1326, 1993
15. Hudis C, Lebwohl D, Crown J, et al: Adjuvant Therapy of Cancer IV, pp 214-219. Philadelphia: Lippincott, 1993.
16. Hudis C, Norton L: Adjuvant drug therapy for operable breast cancer. Semin Oncol 23:475-493, 1996.
17. Skipper HE: Kinetics of mammary tumor cell growth and implications for therapy. Cancer 28:1479-1499, 1971.
18. Norton L, Simon R, Brereton J, et al: Predicting the course of Gompertzian growth. Nature 264:542-545, 1976.
19. Hudis C, Seidman A, Baselga J, et al: Sequential adjuvant therapy with doxorubicin/ paclitaxel/cyclophosphamide for resectable breast cancer involving four or more axillary nodes. Semin Oncol 22(suppl 15): 18-23, 1995.
20. Fennelly D, Schneider J, Spriggs D, et al: Dose escalation of paclitaxel with high-dose cyclophosphamide, with analysis of progenitor-cell mobilization and hematologic support of advanced ovarian cancer patients receiving rapidly sequenced high-dose carboplatin/cyclophosphamide courses. J Clin Oncol 13:1160-1166, 1995.
21. Raptis G, Tiersten A, Fennelly D, et al: The addition of paclitaxel to high-dose cyclophosphamide and filgrastim markedly enhances the mobilization of CD 34+ peripheral blood progenitor cells in patients with responding metastatic breast cancer undergoing high-dose chemotherapy [Abstract]. Proc Am Soc Clin Oncol 14:313, 1995.
22. Hudis C, Seidman A, Raptis G, et al: Sequential dose-dense doxorubicin → paclitaxel → cyclophosphamide is less toxic than doxorubicin → concurrent paclitaxel + cyclophosphamide as adjuvant therapy in resected node positive breast cancer [Abstract]. Proc Am Soc Clin Oncol 15:119, 1996.
23. Gianni L, Munzone E, Capri G, et al: Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer. High antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol 13:2688-2699, 1995.
24. Dombernowsky P, Gehl J, Boesgaard M, et al: Treatment of metastatic breast cancer with paclitaxel and doxorubicin. Semin Oncol 22:13-17, 1995.
25. Sledge GJ: Doxorubicin/paclitaxel combination chemotherapy for metastatic breast cancer: The Eastern Cooperative Oncology Group experience. Semin Oncol 22(suppl 12): 123-129, 1995.